A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
| 대상 질환 | Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Joseph J. Cullen, MD, FACS |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 43 명 |
| 중재(약물) | Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid |
| 시작일 | 2018년 11월 16일 |
| 완료일 | 2025년 7월 15일 |
| 결과 공개일 | 2026년 7월 31일 |
요약
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.
Progression Rate at the Completion of Radiation and Chemotherapy
| ChemoRT + Ascorbate | 6 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC